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Abstract 
Previous studies indicate that 3,4-methylenedioxy-methamphetamine (MDMA, ecstasy) can 
induce heteromeric nicotinic acetylcholine receptor (nAChR, mainly of α4β2 subtype) up-
regulation. In this study we treated male Sprague-Dawley rats twice-daily for 10 days with 
either saline or MDMA (7 mg/kg) and killed them the day after to perform [
125
I]epibatidine 
binding autoradiograms on serial coronal slices. MDMA induced significant increases in 
nAChR density in the substantia nigra, ventral tegmental area, nucleus accumbens, olfactory 
tubercle, anterior caudate-putamen, somatosensory, motor, auditory and retrosplenial cortex, 
laterodorsal thalamus nuclei, amygdala, postsubiculum and pontine nuclei. These increases 
ranged from 3% (retrosplenial cortex) to 30 and 34% (amygdala and substantia nigra). No 
increased α4 subunit immunoreactivity was found in up-regulated areas compared with saline-
treated rats, suggesting a post-translational mechanism as occurs with nicotine. The 
heteromeric nAChR up-regulation in certain areas could account, at least in part, for the 
reinforcing, sensitizing and psychiatric disorders observed after long-term consumption of 
MDMA. 
 
 
Keywords: MDMA; ecstasy; up-regulation; nicotinic receptor; nicotine; epibatidine 
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1. Introduction 
 
3,4-Methylenedioxy-methamphetamine (MDMA
1
, ecstasy) is a psychostimulant and 
entactogen amphetamine derivative used illicitly for recreational purposes. Chronic MDMA 
can induce serotonergic and, to a lesser extent, dopaminergic neurotoxicity in rodents and 
primates (reviewed by Capela et al., 2009). Such neurotoxicity can be a consequence of 
coordinated oxidative stress, metabolic compromise and inflammation (reviewed by 
Yamamoto & Raudensky, 2008) originating upon the interaction of MDMA with several 
targets such as monoamine transporters. Our research group reported a new target for MDMA 
involved in its neurotoxicity: the neuronal nicotinic acetylcholine receptors (nAChR). 
MDMA behaves as a partial agonist on α7 nAChR, inducing prolonged Ca2+ entry, 
which is related with calpain/caspase 3 activation and citotoxicity (Garcia-Ratés et al., 
2010) and as an antagonist on α4β2 nAChR. These effects could attenuate the reported 
protective effect of a full receptor activation (Mudo et al., 2007). In animal and in in 
vitro models, α7 nAChR antagonists have protective effects against MDMA-induced 
neurotoxicity and cognitive impairment (see Pubill et al., 2011 for a review). 
 
nAChR are a family of ligand-gated cation channels widely distributed in the nervous system, 
whose subunit composition and signalling effects depend on subtype and localization 
(Albuquerque et al., 2009; Gotti et al., 2007). They exert relevant effects on brain functions, 
involving fast synaptic transmission, cognitive enhancement, memory or reinforcement, and 
they are the main target of smoked nicotine. nAChR are pentameric structures formed by the 
association of  and  subunits and can be either homomeric or heteromeric. Of these 
combinations, the most abundant are heteromeric (α4)2(β2)3  and homomeric α7 receptors. A 
particular feature of some nAChR subtypes is that, after chronic nicotine exposure, they 
undergo radioligand binding up-regulation, changes in stoichiometry and increase in their 
functional state (functional up-regulation) (reviewed by Gaimarri et al., 2007). Such up-
regulation occurs at a post-translational level and several mechanisms have been proposed to 
explain it, including a chaperone-like maturation enhancing effect of nicotine (Lester et al., 
                                                 
1
 Abbreviations 
5-HT, serotonin; DA, dopamine; DAT, dopamine transporter; MDMA, 3,4-methylenedioxy-methamphetamine; 
nAChR, nicotinic acetylcholine receptor; SERT, serotonin transporter; VTA, ventral tegmental area 
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2009; Kuryatov et al., 2005; Sallette et al., 2005; Srinivasan et al., 2011) and stabilization of 
the high-affinity state of the receptors (Vallejo et al., 2005). Moreover, nAChR up-regulation 
could enhance addiction to nicotine by increasing the pleasant effects of the drug (Govind et 
al., 2009). 
 
Besides its functional effects, we demonstrated that MDMA also induces in vitro up-
regulation of both homomeric and heteromeric receptors on PC12 cells (Garcia-Rates et al., 
2007), through a mechanism that seemed to mimic that of nicotine. Moreover, in recent in 
vivo studies (Pubill et al., 2013; Ciudad-Roberts et al., 2013), we have demonstrated that the 
classic neurotoxic treatment schedule of MDMA in rats (20 mg/kg b.i.d, 4 days) induces 
nAChR up-regulation in gross brain regions thus potentiating the up-regulation induced by 
nicotine; and that a sensitization schedule of MDMA in mice (5 mg/kg/day for 10 days) leads 
to heteromeric nAChR up-regulation in cortex. Changes in these receptors could have a role 
in drug addiction and explain some psychiatric effects of this drug, such as memory 
impairment and psychoses, among others in which nAChR have been found to play a role 
(Levin et al., 2002; Martin et al., 2004; Ripoll et al., 2004). 
 
Accordingly this study had two aims: first to assess whether a more protracted MDMA 
treatment but at a lower dose in rats could induce such up-regulation and, if so, to obtain 
through radioligand binding autoradiography a more precise mapping of the brain areas and 
nuclei that undergo this phenomenon. 
 
2. Material and methods 
 
2.1 Drugs and radioligands 
 
Racemic MDMA hydrochloride was obtained from the National Health Laboratory, 
Barcelona, Spain. Its purity was assessed by spectral analysis. Nicotine bitartrate dihydrate 
and clomipramine were obtained from Sigma (St. Louis, MO, USA). [
3
H]epibatidine, 
[
3
H]paroxetine and [
125
I]epibatidine were obtained from Perkin Elmer (Boston, MA, USA). 
All buffer reagents were of analytical grade and purchased from several commercial sources.  
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2.2 Animals and treatment 
 
The experimental protocols for the use of animals in this study follow the guidelines set out 
by the European Communities Council (86/609/EEC) and were supervised by the ethics 
committee of the University of Barcelona, which specifically approved this study. Efforts 
were made to minimize suffering and reduce the number of animals used. Male Sprague-
Dawley rats weighing 200-230 g (Harlan Ibérica, Barcelona, Spain) were used. They were 
housed at 21ºC ± 1ºC under a 12 h light/dark cycle with free access to food (standard 
laboratory diet, Panlab, Barcelona, Spain) and drinking water.  
 
Treatment 1 was conducted in order to determine in several gross brain regions whether the 
proposed MDMA dosing schedule exerted nAChR up-regulation in a significant manner, 
using radioligand binding to tissue homogenates and Western blotting of lysates. 10 rats were 
used for this assay; 5 were administered saline (1 ml/kg) and 5 were administered MDMA (7 
mg/kg in 1 ml/kg) subcutaneously twice a day within an interval of 7h. The treatment lasted 
10 days and the rats were killed the day after. Given the positive results of this preliminar 
study, the same treatment was repeated with 12 more rats (6 saline, 6 MDMA, treatment 2) 
of the same characteristics, following the same dosing schedule to obtain whole brains in 
order to perform the autoradiography experiments in slices and undertake a more accurate 
localization of the areas where up-regulation takes place. 
 
2.3 Tissue processing 
 
The rats were killed by decapitation under isoflurane anaesthesia and the brains were removed 
rapidly from the skull. In the case of treatment 1, frontal and parietal cortex, striatum, 
hippocampus, and a coronal slice delimited by the thickness of superior colliculi, after 
removal of cortex and hippocampus, (from here on out we will refer to this section as 
“colliculi slice”) were quickly excised on a refrigerated surface, frozen on dry ice and stored 
at –80 °C until later use (Chipana et al., 2008). In the case of treatment 2, whole brains were 
quickly frozen by short immersion in isopentane pre-cooled in dry ice, then stored at -80°C 
until slicing for autoradiography experiments. 
 
Samples for use in radioligand binding experiments or Western blot determination were 
thawed and homogenized in 10 volumes of buffer: 5 mM Tris-HCl, 320 mM sucrose and 
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 6 
protease inhibitors (aprotinin 4.5 μg/μl, 0.1 mM phenylmethylsulfonyl fluoride and 1 mM 
sodium orthovanadate), pH 7.4, with a Polytron homogenizer. The homogenates were 
centrifuged at 15,000 x g for 30 min at 4 °C. The resulting pellets were washed twice and the 
final pellets (crude membrane preparation) were resuspended in 50 mM Tris-HCl buffer. 
Protein concentration was determined using the BioRad protein reagent (Bio-Rad Labs. Inc., 
Hercules, CA, USA) according to the manufacturer’s instructions and the samples were stored 
at -80 ºC until later use.  
 
For Western blotting, aliquots of tissue homogenates were centrifuged at 15,000 x g for 30 
min at 4ºC. The supernatants were discarded and the pellets were resuspended in an 
appropriate volume of ice-cold solubilisation buffer consisting of 20 mM Tris HCl pH 8, 137 
mM NaCl, 2 mM EDTA, 1% Nonidet P-40, 4.5 µg/µl aprotinin and 0.1 mM 
phenylmethylsulfonyl fluoride. Proteins were solubilised by incubation for 2 h at 4ºC under 
gentle rotation. Thereafter, the samples were centrifuged at 15,000 x g for 30 min at 4ºC and 
the supernatants were stored at -80 ºC after determination of protein content using the Bio-
Rad Protein Reagent and bovine serum albumin standards prepared in the same dilution of 
solubilisation buffer, in order to compensate for the reaction with the buffer detergent. 
 
The samples for use in autoradiography experiments were processed as follows: brains were 
coronally-sectioned (16 μm thickness) using a Leica CR 3050 S cryostat (chamber 
temperature: -20 ºC; sample temperature: -16 ºC). Sections were thaw-mounted on Fisher 
Superfrost Plus microscope slides and immediately returned to the cryostat chamber until 
storage. Two consecutive sections were mounted on each slide. The slides containing the 
sections were stored in tightly sealed containers with Drierite bags at –80ºC until use. The 
sections were numbered according to the most approximate coordinates obtained from the 
Paxinos & Watson rat brain atlas (2005). 
 
2.4 Radioligand binding assays 
 
[
3
H]paroxetine binding was used to label serotonin (5-HT) transporters (SERT) in order to 
assess whether MDMA dosage had caused any serotonergic alterations, including neurotoxic 
effects (Pubill et al., 2003). Binding was determined in membrane preparations from parietal 
cortex, an area very sensititive and representative to the effects of MDMA on SERT. Binding 
was performed in glass tubes containing 0.1 nM [
3
H]paroxetine and 150 μg of membranes. 
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Incubation was carried out at 25 ºC for 2 h in a Tris–HCl buffer (50 mM, pH 7.4) containing 
120 mM NaCl and 5 mM KCl to a final volume of 1.6 ml. Clomipramine (100 μM) was used 
to determine non-specific binding.  
 
[
3
H]epibatidine binding was used to label heteromeric (mainly α4β2) nAChR in order to 
determine whether MDMA had caused an up-regulation of these receptor types in the gross 
regions obtained from treatment 1. Concretely, binding was carried out using preparations 
from rat cortex, striatum and the “colliculi slice”. These experiments were performed in glass 
tubes containing 1 nM [
3H]epibatidine and 200 μg of brain membranes. Incubation was 
carried out at 25 ºC for 2 h in Tris-HCl buffer (50 mM, pH 7.4). Nicotine (300 μM) was used 
to determine non-specific binding.  
 
Bindings were terminated by rapid vacuum filtration through Whatman GF/B glass fibre 
filters (Whatman Intl. Ltd., Maidstone, U.K.) presoaked in 0.5% polyethyleneimine. Tubes 
and filters were washed rapidly 3 times with 4 ml ice-cold 50 mM Tris-HCl. The radioactivity 
trapped on the filters was measured by liquid scintillation spectrometry. Specific binding was 
calculated as the difference between the radioactivities measured in the absence (total 
binding) and in the presence (non-specific binding) of the excess of non-labelled ligand. 
 
2.5 Western blotting and immunodetection  
A general Western blotting and immunodetection protocol was used to determine nAChR 4 
subunit in the frontal cortex and colliculi slice extracts from treatment 1, which had shown 
significant [
3
H]epibatidine binding up-regulation. For each sample, 30 μg of protein was 
mixed with sample buffer [0.5 M Tris-HCl, pH 6.8, 10% glycerol, 2% (w/v) sodium dodecyl 
sulphate, 5% (v/v) 2--mercaptoethanol, 0.05% bromphenol blue, final concentrations], 
boiled for 10 min, loaded onto a 10% acrylamide gel and separated by electrophoresis. 
Proteins were then transferred to polyvinylidene fluoride membranes (Immobilon-P, 
Millipore, Billerica, MA, USA). Membranes were blocked 1 h at room temperature with 5% 
bovine serum albumin in Tris-buffered saline buffer plus 0.05% Tween 20 (TBS-T) and 
incubated overnight at 4ºC with a primary rabbit monoclonal antibody against nAChR α4 
subunit (ab124832) purchased from Abcam (Cambridge, UK) and used at a 1:1000 dilution in 
TBS-T buffer plus 5% bovine serum albumin. After washing, the membranes were incubated 
with a peroxidase-conjugated anti-rabbit IgG antibody (GE Healthcare, Buckinghamshire, 
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UK). Immunoreactive protein was visualized using a chemiluminescence-based detection kit 
(Immobilon Western, Millipore) and a BioRad ChemiDoc XRS gel documentation system. 
Apparent molecular weight bands corresponding to the target protein was 70 kDa. Scanned 
blots were analyzed using BioRad Quantity One software. Immunodetection of β-actin 
(mouse monoclonal anti β-actin antibody, Sigma, St. Louis, USA; dil.1:2500) served as a 
control of load uniformity for each lane and was used to normalize differences due to protein 
content. The α4 levels are expressed as a percentage of those obtained from saline-treated 
animals.  
 
2.6 Autoradiography experiments 
 
Slides containing the brain sections were removed from the -80ºC freezer and left to warm to 
room temperature. A hydrophobic barrier was drawn around every slice using an ImmEdge™ 
Pen (Vector Laboratories, Burlingame, CA, USA) to provide a heat-stable, hydrophobic 
barrier that kept reagents localized on tissue specimens and prevented mixing when multiple 
sections were mounted on the same slide.  
 
The binding of [
125
I]epibatidine to brain slices was conducted as follows. After warming, the 
slides (containing two slices each) were placed on a flat surface and 0.5 ml of binding buffer 
(50 mM Tris-HCl buffer, pH 7.4; aprotinin 4.5 μg/μl; 0.1 mM phenylmethylsulfonyl fluoride) 
was distributed onto each sample during 15 min. Thereafter, buffer was aspirated and the 
samples were pre-incubated again for another 15 min in binding buffer.  
 
In preliminary experiments, one section of each slide was incubated during 1 h in binding 
buffer containing 0.2 nM [
125
I]epibatidine and, in order to determine the non-specific binding, 
the adjacent section was incubated in [
125I]epibatidine containing 300 μM nicotine. Under 
these conditions, non-specific binding in adjacent sections was not distinguishable from 
background and therefore total binding was identical to specific binding, as previously 
reported by other groups (Nguyen et al., 2003). Thus further sections were incubated only 
with [
125
I]epibatidine to obtain a larger number of sections to quantify. After incubation, the 
radioligand was aspirated and the samples were washed by immersing each slide in two 
cubets filled with ice-cold 50 mM Tris-HCl buffer during 5 min each. Samples were finally 
dipped in ice-cold bidistilled water to remove salts and quickly dried using a stream of cold 
dry air. 
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 Once slides were completely dry, they were stuck onto a cardboard paper sheet using double-
sided tape, together with [
125
I] standards (American Radiolabeled Chemicals, St. Louis, MO, 
USA). Slides were then placed into an exposition cassette and covered with a plastic sheet and 
a phosphor plate (storage phosphor screen GP, Kodak, Rochester, NY, USA) on top of it. 
Expositions lasted 24-48 h depending on the signal intensity of the areas of interest and plates 
were scanned at maximum resolution using a phosphorimager (BioRad Personal Molecular 
Imager, Bio-Rad Labs. Inc., Hercules, CA, USA).  
 
The autoradiography images were processed using BioRad Image Lab software, where each 
area or region of interest (ROI) was manually delineated as closely as possible to the 
actual area delimited by the Paxinos & Watson atlas (2005). The ROI shape was 
copied/pasted and fitted to the same area of similar slices. Different shapes were made 
for left and right hemispheres in order to properly adjust to each area. The 
corresponding intensity and area values were exported to Microsoft Excel. The mean density 
count (counts/area) was calculated, the background subtracted and bound radioactivity was 
determined through 2
nd
 order polynomial (quadratic) interpolation in the curve defined by 
radioactivity standards using GraphPad Prism 3.0 software. Values were normalized taking 
into account the radioactivity decay of the radioligand and the standards for each 
determination day. All the intensity values of the samples fell within the standard curve 
defined by the radioactivity standards, where the relationship between activity and intensity 
was practically linear. Data (mean ± SEM) are reported in normalized arbitrary units (AU). 
 
For each rat and brain area, at least 6 values were obtained from different slices and 
averaged. According to the Paxinos and Watson atlas (2005), the caudate-putamen was 
divided into anterior (plates 13-15) and posterior (plates 16-39) and data represent 
measurements of the entire area at those levels. Also, thalamic nuclei were grouped into 
laterodorsal, medial, ventral and ventral pallidum. For visualization purposes, images were 
converted from grayscale to color spectrum using the Image Lab software. 
 
Note that although a large number of regions (31) were assessed, this was not an exhaustive 
survey of binding in all brain regions, but a demonstration that MDMA can induce regional 
nAChR up-regulation.  
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2.7 Statistical analysis 
 
All data are expressed as mean ± standard error of the mean (S.E.M.) of the values obtained 
for each treatment group. Unpaired Student’s t-test for two-sample (saline vs. MDMA) was 
used to analyse the statistical significance (P<0.05) of the difference between the means of the 
two groups. Values of t-test and dregrees of freedom (df) are also reported for each 
comparison.  
 
3. Results 
 
3.1 [
3
H]Paroxetine binding 
 
There was a significant marked decrease (around 50%) in [
3
H]paroxetine binding in parietal 
cortex from the rats treated with MDMA and killed the day after the last dose (t = 2.88, df = 
8, P = 0.02), thus indicating a loss of serotonin transporters (Fig. 1). 
 
3.2 [
3
H]Epibatidine binding to homogenates 
 
Significant increases (P<0.05) in [
3
H]epibatidine binding were found in the frontal portion of 
the cortex (24%, t = 3.42, df = 7, P = 0.014) and the colliculi slice (28%, t = 5.21, df = 8, P = 
0.0008,  this slice contains the colliculi, the geniculate nuclei, the substantia nigra (SN) and 
the ventral tegmental area, (VTA)) originating from MDMA-treated rats (Fig. 2). No 
significant increases were found in the striatum (t = 2.023, df = 8, P = 0.08) or in the parietal 
cortex (t = 2.24, df = 7, P = 0.06) although a tendency towards increase can be observed. 
 
3.3 Western blot of α4 protein 
 
In order to determine whether the increase in α4β2 nAChR observed in treatment 1 was due to 
increased protein synthesis or to post-translational modifications, α4 subunits were 
immunodetected in the lysates from the areas where significant increases in [
3
H]epibatidine 
binding were found, namely the frontal cortex and the colliculi slice . No significant changes 
were observed between the subunit levels of saline and MDMA-treated rats (Fig. 3) (frontal 
cortex: t = 0.59, df = 8, P = 0.57; colliculi slice: t = 0.25, df =8, P = 0.80). 
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3.4 [
125
I]Epibatidine autoradiography 
 
[
125
I]Epibatidine labelled heteromeric nAChR in accordance with the established patterns in 
previous publications (i.e. Nguyen et al., 2003; Tribollet et al., 2004). Intermediate nAChR 
levels were found in cortex, striatum, thalamic nuclei, geniculate nuclei and SN. Receptor 
density was most intense in the superior colliculi, medial habenula and interpeduncular 
nucleus, while hippocampus and hypothalamus showed the lowest nAChR levels.  
 
MDMA-treated animals showed a significant increase in nAChR density in the SN, VTA, 
nucleus accumbens, olfactory tubercle, anterior caudate-putamen, somatosensory, motor, 
auditory, and retrosplenial cortex, laterodorsal thalamuic nuclei, amygdala, postsubiculum 
and pontine nuclei (Table I). These increases (Table 1 and Fig. 4) ranged from 3% 
(retrosplenial cortex) to 30 and 34% (amygdala and SN). The rest of areas showed no 
significant difference between saline and MDMA-treated rats. 
 
Discussion 
 
In this study we have demonstrated, using the radioligand autoradiography technique, that a 
prolonged treatment with the psychostimulant drug MDMA induces up-regulation of 
heteromeric nAChR (which in the brain are mainly α4β2) in specific areas of the rat brain. 
This is in agreement with our previous reports showing this effect in cultured PC 12 cells 
(Garcia-Ratés et al., 2007), in gross brain areas after the classical neurotoxic schedule (Pubill 
et al., 2013) or in mice after a sensitizing schedule (Ciudad-Roberts et al., 2013). MDMA has 
affinity for α4β2 nAChR (Garcia-Ratés et al., 2007; Chipana et al., 2008) as occurs with 
several nicotinic ligands, either agonists or antagonists, that have been reported to induce 
nAChR up-regulation (Peng et al., 1994; Gopalakrishnan et al., 1997).  
 
Binding to homogenates from gross brain areas is useful for screening purposes, but is not 
accurate enough to ascertain the changes in small areas that are involved in specific brain 
functions. Also, if the increase took place only in a small area that is part of a gross portion 
used for the assay, this increase would not be detected owing to the dilution effect (as we 
found, for example, in the different parts of the striatum). Thus, looking at the previous 
results, it was mandatory to carry out an autoradiography study in brain slices to determine 
nAChR levels in more defined areas.  
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In addition, we used lower MDMA doses than in the previous study (Pubill et al., 2012), 
during an extended treatment period at normal housing temperature in order to reduce 
serotonergic neurotoxicity that could hinder nAChR up-regulation (Gordon et al., 1991; 
Green et al., 2005). In this respect we must point out that regardless of the conditions of this 
treatment, we found a marked loss of paroxetine binding sites, which has been generally 
linked to serotonergic neurotoxicity. However, we must point out that in our treatment the rats 
were killed 24 h after the last dose, while most studies (i.e. Biezonski & Meyer, 2010; 
Broening et al., 1995; Malberg et al., 1998; O’Shea et al., 1998) make the measurement after 
leaving a time of at least one week to allow the neurotoxic process to occur. We cannot assert 
whether the decrease in paroxetine binding is due to serotonergic terminal degeneration or to 
a regulatory process. In fact, a significant reduction in SERT gene expression, which could 
explain a reduction in SERT protein irrespective of altered terminal integrity, has been 
reported after treatment with MDMA (Biezonski & Meyer, 2010). As will be discussed 
below, as a number of presynaptic nAChR are localized on serotonergic terminals and there 
seems to be a positive correlation between their up-regulation and SERT, it can be suggested 
that the decrease in paroxetine binding in this study is most likely to be due to a regulatory 
process rather than to terminal destruction.  
As most up-regulation studies carrried out with nicotine use continuous dosing through 
prolonged constant infusion or osmotic minipumps (i.e. Nguyen et al., 2003) we chose a 
MDMA dosing schedule aimed to reach sufficient plasma levels during enough time to induce 
up-regulation with reduced neurotoxic potential, compared with our previous work in gross 
brain areas. This schedule, therefore, was not intended to model any human consumption 
pattern but to demonstrate and localize nAChR up-regulation by MDMA. Once this was 
demonstrated, further work using other schedules closer to recreational use patterns should be 
performed.  
Phosphor imaging was used in order to obtain and quantify the images. Traditionally, in situ 
autoradiography has been performed using X-ray film, which provides the highest resolution. 
However, depending on the radioligand used, exposure times with films are much longer than 
those with phosphor plates and, due to the evolution and raise of the digital imaging systems, 
obtaining suitable and affordable X-ray films is becoming more and more difficult. As an 
alternative, quantitative phosphor imaging provides lower exposure time, economization due 
to the reutilization of phosphor screens, no waste of developing solutions, direct 
quantification on the scanned digital image and an optical resolution suitable for most 
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quantitative purposes (Strome et al., 2005). This technique was used by another group for 
quantifying α7 nAChR using [3H]methyllycaconitine (Mugnaini et al., 2002) and, to our 
knowledge, the present study is the first employing this technique to quantify heteromeric 
nAChR using [
125
I]epibatidine. 
 
A number of studies carried out with nicotine have suggested several mechanisms to explain 
nAChR up-regulation (see Introduction), and most agree on the fact that up-regulation occurs 
at a post-translational level. To assess this possibility with MDMA we analyzed by Western 
blot the α4 subunit levels in the same protein samples from brain portions that had showed 
increased epibatidine binding in homogenates and compared them with those from saline-
treated rats. No significant differences were found between the two groups, indicating that up-
regulation of binding takes place without increased protein levels, probably through post-
translational modifications that increase the affinity or promote maturation of receptors 
towards a form capable of binding the ligand, similarly to what has been described for 
nicotine in the articles referenced above.  
 
nAChR have a predominant presynaptic localization, on the nerve endings, where they 
modulate the release of key neurotransmitters such as acetylcholine, dopamine (DA), GABA, 
glutamate and serotonin (reviewed by Marchi & Grilli, 2010), although they are also at the 
preterminal level and on different postsynaptic locations in the brain (Mameli-Engvall et al., 
2006). NAChR play a key role in addiction to nicotine (Govind et al., 2009). It has been 
described that the addictive effects of nicotine are produced through its interaction with 
nAChR in the mesolimbic pathway, especially those in the nucleus accumbens, leading to DA 
release that activates the reward circuitry. In fact, mice with deletion of the β2 gene do not 
self-administer nicotine after previous administration and do not show increased release of 
DA in the ventral tegmental area (Picciotto et al., 1999).  
Although the mechanisms involved in the establishment of addiction are complex and still 
being investigated, up-regulation of nAChR increasing the pleasant effects of the drug is an 
event that could feasibly play a role. In the present study, we demonstrate nAChR up-
regulation in key areas involved in addiction, such as the VTA, the nucleus accumbens and 
several areas of the cortex that are involved in sensory and motor functions (i.e. auditory, 
somatosensory, motor), as well as in the olfactory tubercle. Heteromeric nAChR play a role in 
the hyperlocomotion induced by amphetamine derivatives (Camarasa et al., 2009; Ciudad-
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Roberts et al., 2013), thus an increase in nAChR in these areas could account for sensitization 
to the locomotor effects and the addictive properties of MDMA. In fact, blockade of nAChR 
containing the α4 subunit with dihydro-β-erythroidine or varenicline inhibits the 
hyperlocomotion induced by MDMA in mice, as well as an increased delayed sensitization 
(Ciudad-Roberts et al., 2013). Moreover, in the same study it was demonstrated that 
pretreatment with nicotine inducing nAChR up-regulation reduced the dose threshold for 
MDMA-conditioned place preference.  
In the olfactory tubercle, an area that underwent a 20% increase, β2 subunit-containing 
nAChR increase DA release (Grady et al., 2002). This area is a component of the ventral 
striatum, it is heavily interconnected with several affective, reward and motivation related 
centers of the brain, being the area that modulates behaviour during certain physiological and 
mental states (Weeson & Wilson, 2011). The olfactory tubercle has also been shown to be 
especially involved in reward and addictive behaviours, so that rats have been shown to self-
administer cocaine into this area more than the nucleus accumbens and ventral pallidum 
(Ikemoto, 2003). Also, the olfactory tubercle receives an important serotonergic innervation 
(Cumming et al., 1997). Therefore the up-regulation found in this area could also account for 
reinforcing effects after a chronic treatment. 
 
The nigrostriatal pathway was also affected by nAChR up-regulation, as we found a 33% 
increase in subtantia nigra as well as a 16% increase in the anterior caudate-putamen. α4β2 
nAChR have been identified in soma and dendrites of SN, as well as in the dopaminergic 
terminals in the striatum (Jones et al., 2001). Dopaminergic neurones from the SN possess the 
ability to release DA not only from axon terminals in striatum, but also from the soma and 
dendrites within SN (Cheramy et al., 1981). It has been suggested that serotonergic afferents 
to SN may evoke this dendritic dopamine release through a mechanism that is uncoupled from 
the impulse-dependent control of nerve terminal DA release (Cobb & Abercrombie, 2003).   
 
Nicotine and nicotinic agonists increase DA release from mesolimbic and nigrostriatal 
neurones in vitro and in vivo (Wonnacott, 1997). In the striatum, an important percentage of 
β2 subunit-containing nAChR is associated to dopaminergic buttons from the nigrostriatal 
pathway, and the rest may correspond to other neurotransmitter afferents such as serotonergic 
fibers coming from the dorsal raphe nucleus (Jones et al., 2001; Reuben & Clarke, 2000; 
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Schwartz et al., 1984). As this pathway is involved in the control of movement, increased 
nAChR in the striatal DA terminals could be involved in motor disorders or stereotypies. 
 
Previous studies on nicotine-induced nAChR up-regulation indicate that chronic nicotine 
exposure differentially affects the number (up-regulation), subunit composition, stochiometry 
and functional status of some nAChR subtypes, leaving others substantially unaffected 
(Gaimarri et al., 2007). In this respect, when comparing the results of the present study with 
those obtained from chronic nicotine-treated rats by Nguyen et al. (2003) in the same brain 
areas, we can find similarities regarding these aspects. For example, in both studies, the 
amygdala and the substantia nigra exhibit some of the highest up-regulation rates, while other 
areas with a high density of nAChR such as the interpeduncular nucleus or the medial 
habenula show no change in radioligand binding. The nucleus accumbens undergoes the 
highest up-regulation in the corpus striatum, while in the caudate-putamen it is more modest. 
Conversely, some areas within the cortex and the hippocampus that had shown robust nAChR 
up-regulation after nicotine administration were unaffected or showed a lower effect in our 
study. We have cited above that nAChR up-regulation by nicotine and MDMA is a 
mechanistically-complex process that implies the interaction of the ligand with intracellular 
immature forms of the receptor. Nicotine is known to penetrate the cell membrane (Whiteaker 
et al., 1998), which allows such an interaction to occur, while MDMA is known to use the 
monoamine transporters, mainly the SERT (Fitzgerald et al., 1990), to access the intracellular 
compartments. Thus the different ability of each brain area to take up MDMA could explain 
the main differences found in comparison to nicotine.  
 
Moreover, when looking at previous literature such as the article from Battaglia et al. 
(1991), who similarly quantified the levels of SERT in brains from rats of the same 
strain, gender and age than ours, we found that the areas with increased epibatidine 
binding tend to correspond with areas having higher SERT levels in control animals. In 
fact, it has been reported that a single acute in vivo exposure to nicotine significantly increases 
5-HT uptake via SERT in prefrontocortical synaptosomes (Awtry & Werling, 2003), which 
indicates that there is a regulatory interaction between nAChR and SERT. In this respect we 
noticed that SERT density in the areas showing greatest nAChR up-regulation by MDMA 
was not affected (amygdala and VTA) or even increased (substantia nigra, nucleus 
accumbens) by MDMA in the study from Battaglia et al. (1991). On the other hand, areas 
from the cortex and hippocampus which are capable of showing a robust nAChR up-
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regulation by nicotine, suffer from a strong reduction of SERT after MDMA, as we also 
assessed in cortex homogenate in the present study; this could explain why these areas show a 
lower radioligand binding increase after treatment with this amphetamine derivative, as this 
would difficult its internalization in the synaptic terminal, thus impeding nAChR up-
regulation. Nonetheless, further investigation should be conducted to pursue this 
hypothesis. 
 
The predominantly presynaptic localization and widespread distribution of nAChR in several 
brain circuits makes it particularly difficult to functionally characterize the specific behavioral 
or brain roles affected by MDMA-induced up-regulation; nonetheless the present results can 
illustrate which functions could probably be altered and suggest a mechanism to explain, at 
least in part, the reinforcing properties of MDMA. 
 
Conclusion 
In this study we demonstrate that a protracted treatment with MDMA induces heteromeric 
nAChR up-regulation in key areas of rat brain involved in motivation and learning, sensory 
and movement control, which could account for reinforcing and some neuropsychiatric 
disorders related with chronic consumption of this drug. 
Translated to a clinical context, we show nAChR as a potential target for reducing 
MDMA’s reinforcing effects. Furthermore, we also postulate that nAChR up-regulation 
induced by chronic consumption of MDMA could potentiate the ability of other drugs to 
cause addiction due to an enhancement of nAChR-mediated reinforcing effects. 
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Table 1. [125I]Epibatidine binding to several brain areas of saline- and MDMA-
treated rats. 
Area Saline MDMA t, df P Increase (%) 
Frontal cortex 23.53 ± 0.98 23.69 ± 0.65 0.123, 9 n.s.  
Anterior olfactory 
nucleus 
15.45 ± 1.03 14.64 ± 0.92 0.586, 8 n.s.  
Nucleus accumbens 23.69 ± 0.84 27.79 ± 1.19 2.815, 10 <0.05  17 
Cingulate  cortex 24.85 ± 0.78 25.88 ± 0.72 0.970, 10 n.s.  
Motor cortex 21.07 ± 0.32 23.07 ± 0.80 2.321, 8 <0.05  10 
Somatosensory 
cortex  
26.25 ± 0.44 28.86 ± 0.93 2.368, 9 <0.05  10 
Insular cortex  16.57 ± 1.44 16.85 ± 0.93 0.163, 10 n.s.  
Olfactory tubercle 18.81 ± 0.89 22.62 ± 0.34 3.697, 9 <0.01  20 
Retrosplenial cortex 31.10 ± 0.26 32.14 ± 0.27 2.739, 9 <0.05  3 
Visual cortex 23.22 ± 0.60 24.83 ± 2.06 0.750, 10 n.s.  
Auditory cortex 25.79 ± 0.49 28.76 ± 1.06 2.371, 9 <0.05  12 
Caudate-putamen 
anterior 
posterior 
 
31.91 ± 1.73 
21.62 ± 2.44 
 
37.03 ± 1.68 
21.77 ± 0.72 
 
2.253, 10 
0.059, 10 
 
<0.05  
n.s. 
 
16 
Hippocampus (CA1) 13.94 ± 0.68 14.92 ± 0.57 1.104, 10 n.s.  
Hippocampus 
(dentate gyrus) 
19.32 ± 2.58 18.98 ±1.42 0.115, 10 n.s.  
Medial habenula 83.57 ± 3.21 79.79 ± 3.73 0.768, 8 n.s.  
Ventral pallidum 57.99 ± 1.35 58.08 ± 1.46 0.045, 10 n.s.  
Laterodorsal thalamic 
nuclei 
69.68 ± 1.93 77.33 ± 1.77 2.921, 10 <0.01  11 
Ventral   thalamic 
nuclei 
66.08 ± 1.62 65.38 ± 0.62 0.403, 10 n.s.  
Medial thalamic 
nuclei 
60.69 ± 1.41 61.08 ± 1.86 0.167, 10 n.s.  
Hypothalamus 23.22 ± 0.60 24.83 ± 2.06 0.815, 9 n.s.  
Amygdala 15.78 ± 1.27 20.48 ± 0.89 3.031, 10 <0.05  30 
Dorsal lateral 
geniculate nuclei 
57.96 ± 6.45 49.49 ± 3.09 1.184, 8 n.s.  
Superior colliculus, 
superficial gray layer  
49.97 ± 4.12 52.13 ± 1.52 0.492, 8 n.s.  
Medial geniculate 
nuclei 
35.3 ± 4.65 38.97 ± 1.09 0.768, 8 n.s.  
Substantia nigra 27.52 ± 3.59 36.81 ± 0.96 2.287, 9 <0.05  34 
Ventral tegmental 
area 
27.47 ± 1.69 33.15 ± 0.69 3.112, 10 <0.05  21 
Pontine nuclei 19.37 ± 0.39 22.72 ± 1.12 2.825, 8 <0.05  17 
Interpeduncular 
nucleus 
81.51 ± 2.92 91.41 ± 4.78 1.767, 8 n.s.  
Postsubiculum 46.33 ± 1.8 52.4 ± 1.24 2.777, 8 <0.05  13 
Cerebellum 10.45 ± 0.52 10.20 ± 0.49 0.350, 8 n.s.  
Semi-quantitative analysis of [
125
I]epibatidine binding to several areas of brain slices from rats treated 
with saline (Ctrl) or MDMA (7 mg/kg/day, b.i.d, 10 days). Data (mean ± SEM from 5-6 animals per 
group) are reported in normalized arbitrary units. P indicates the degree of statistical significance; n.s., 
non significant (P>0.05); t is Student’s t value and df is the degrees of freedom. 
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Figure captions 
 
Figure 1. 
Levels of serotonin transporters (SERT), measured as [
3
H]paroxetine binding, in membranes 
from parietal cortex of saline- and MDMA-treated rats. Male Sprague-Dawley rats were 
treated for 10 days b.i.d. with a dose of MDMA (7 mg/kg) or saline and were sacrificed the 
day after after. Results are shown as mean ± SEM of the values from 6 animals per group. 
**P<0.01 vs. saline group. 
Figure 2. 
Density of heteromeric nAChR, measured as [
3
H]epibatidine binding, in membranes from 
gross areas of brains from saline- and MDMA-treated rats. Rats were treated for 10 days b.i.d. 
with a dose of MDMA (7 mg/kg) or saline and were sacrificed on day 11. Binding was 
assessed in frontal cortex (Fr-CTX), parietal cortex (Par-CTX), the coronal slice of 
mesencephalon defined by the thickness of superior colliculi (Col. slc) and the striatum (ST). 
Results are shown as mean ± SEM of the values from 6 animals per group. * P<0.05 and 
***P<0.001 vs. the same area of saline group. 
Figure 3. 
Western blot analysis of α4 nAChR subunit in protein extracts of the colliculi slice (Col. slc) 
and frontal cortex (Fr-CTX) from rats treated for 10 days b.i.d. with a dose of MDMA (7 
mg/kg) or saline and sacrificed the day after. Bar graph (panel A) shows overall quantification 
expressed as percentage over control (6 animals per group, mean ± SEM), while a 
representative autoradiography from each area (panels B and C) is shown below. β-actin 
levels were used to ensure gel-loading uniformity and normalize the protein values 
accordingly. 
 
Figure 4. 
Representative images of [
125
I]epibatidine binding to brain slices from rats treated for 10 days 
b.i.d. with saline or MDMA (7 mg/kg) and sacrificed the day after. All the labelled regions 
are illustrated. Numbers on the bottom left corner of photographs indicate the approximate 
distance of the sections from the coronal plane passing through bregma according to Paxinos 
and Watson (2005). Panel A shows the grayscale scanned images, while panel B shows the 
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same images converted to colour spectrum which allows improved visual appreciation of the 
receptor densities. Abbreviations used (in order of appearance): Fr, frontal cortex; AO, 
anterior olfactory nucleus; Acb, nucleus accumbens; Cg, gingulate cortex; M, motor cortex; S, 
somatosensory cortex; I, insular cortex; OT, olfactory tubercle; RS, retrosplenial cortex; V, 
visual cortex; Au, auditory cortex; HC, hippocampus; MHb, medial habenula; VP, ventral 
pallidum; LD, laterodorsal thalamic nuclei; VThn, ventral thalamic nuclei; MThn, medial 
thalamic nuclei; HT, hypothalamus; Amy, amygdala; DLG, dorsal lateral thalamic nuclei; 
SuG, superior colliculus, superficial gray layer; MG, medial geniculate nuclei; SN, substantia 
nigra; VTA, ventral tegmental area; PN, pontine nuclei, IP, interpeduncular nucleus; P, 
postsubiculum, CB, cerebellum. 
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